2014 is bound to go down as the year of med tech merger mania. FierceMedicalDevices compiles the year's 10 biggest medical device and diagnostic mergers.
Takeda's CEO-in-waiting, Christophe Weber, has included emerging markets, along with oncology and gastrointestinal medicines, as one of three areas of focus. He recently said he is ready to do some deals to capitalize on those areas, and now he has executed one that straddles two of those favorites.
Fresh from completing a $5 billion deal for NPS Pharma, Shire stopped to bag a small San Diego biotech, picking up Meritage Pharma and a Phase III-ready rare disease drug for $70 million upfront and a slate of unspecified milestones.
PTC Therapeutics is looking to get bought, Reuters ' sources say, betting that a larger company will covet its treatment for Duchenne muscular dystrophy enough to overlook a checkered history.
Medtronic has just disclosed that it bought Advanced Uro-Solutions in December 2014 for an undisclosed amount. In August 2013, the FDA cleared the startup's neurostimulation device, the Nuro System, to treat overactive bladder and its associated symptoms of urinary urgency, urinary frequency and urge incontinence.
It didn't take long for serial acquirer Valeant to jump back into the dealmaking saddle after failing to snag Allergan last year. Now, the Canadian pharma has inked its second agreement of the month--a $10.1 billion pickup of North Carolina's Salix Pharmaceuticals that will ring in as its largest deal ever.
Acquisitive Chinese CRO WuXi PharmaTech is borrowing up to $165 million to keep up its string of deals, eyeing investments in R&D and manufacturing.
A deal that was rumored this summer now looks like it's ready to come to pass. Johnson & Johnson is ready to sell off its Cordis business to Cardinal Health for as much as $2 billion, according to report by Bloomberg. Cordis has elicited multiple offers from bidders, some of whom may still be in the running.
Bristol-Myers Squibb is gambling $800 million upfront to gain control of a preclinical IDO1 immunotherapy that shows promise in treating cancer, buying out San Carlos, CA-based Flexus with another $450 million set aside for milestones.
Hilary Kramer is a high-profile lawyer, stock picker and television commentator who has filed more than 40 class-action lawsuits against companies planning mergers or acquisitions, mostly on the grounds that the deals are unfair to shareholders. Among her targets: Animal Health International, a maker of drugs for livestock that was acquired by rival Lextron in 2011 for $251 million.